GENETIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET ANALYSIS

Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Drug Class (Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Steroids, Antibiotics and Others), By Route of Administration (Oral and Nasal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jan 2023
Code : CMI5512
Pages :178
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Key Players

Major players operating in the global genetic chronic obstructive pulmonary disease (COPD) market include GSK Plc, AstraZeneca Plc, Merck (Sigma-Aldrich), Dey Pharma, Grifols, S.A., Teva Pharmaceutical Industries Ltd, Baxter, Boehringer Ingelheim International GmbH, Kamada Ltd, Takeda Pharmaceutical Company Limited, LFB SA, Abeona Therapeutics, Alnylam Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Kedrion S.p.A., and Arrowhead Pharmaceuticals, Inc.

Genetic Chronic Obstructive Pulmonary Disease (COPD) Market Report Snapshots